

ANDA vs. 505(b)(2) NDA

Determining the Pathway

Charles Bon, M.S.
Loren Gelber, Ph.D



Topics to be covered

- ANDA 505(j) Applicability
- NDA 505(b)(2) Applicability
- ANDA vs. NDA 505(b)(2)
Process
- Regulatory Landscape
- Exclusivity

Topics to be covered

- Required Data
- Costs
- Timelines
- Examples
- Marketing Options

ANDA 505(j) Applicability

21 CFR 314.92

Abbreviated applications may be submitted for:

- Drug products that are the same as a listed drug
 - identical in active ingredient (s)
 - Identical in form
 - Identical in strength
 - Identical in route of administration
 - Identical in conditions of use (non-exclusive uses)
- Products declared suitable based on petition to FDA

ANDA 505(j) Applicability

§ 314.93 Petition

- API same pharmacological/therapeutic class as RLD
- Same therapeutic effect as RLD for indications desired
- If combo product with one different API, it is not “new”
- For a change in API, product must be combo one
- The label must not differ significantly from RLD label
- RLD has not been discontinued due to safety or efficacy

NDA 505(b)(2) Applicability

21 CFR 314.54

- Full Reports of Safety and Effectiveness
 - Info from studies not conducted by applicant
 - Info where applicant lacks the right of reference
- Types of products
 - New Chemical or New Molecular Entity
 - Changes to Previously Approved Drugs (RLD)
 - New Dosage Form, Strength, Route of Administration
 - Substitution of an Active Ingredient in Combo Product
 - Formulation changes outside 505(j) limits

NDA 505(b)(2) Applicability

- Changes to Previously Approved Drugs (cont.)
 - Dosage Regimen
 - API change – salt, ester, complex, chelate, racemate, enantiomer, etc.
 - New Indication
 - Rx/OTC switch
 - Bioinequivalent to, but not inferior BA than, RLD
- Excluded Products
 - Product covered by 505(J)
 - Only difference is lower extent than RLD
 - Only difference is unintended lower rate than RLD

ANDA 505(j) vs. NDA 505(b)(2)

- Process
- Regulatory Landscape
- Exclusivity
- Required Elements
- Time
- Cost

ANDA vs. NDA 505(b)(2) Process

	ANDA	NDA
Formulate	X	X
Manufacture	X	X
Stability	X	X
Meet w/FDA		X
PK Study	X	X
Clinical Trial	*	*
Meet w/ FDA		X
Submission	X	X

ANDA vs. NDA 505(b)(2) Process (cont.)

- * Need clinical or PD with topical product for ANDA – Do not always need clinical for 505(b)(2) NDA.

ANDA Regulatory Landscape

Office of Generic Drugs

Division of
Bioequivalence

ANDA Filing

- Paragraph 1
- Paragraph 2
- Paragraph 3
- Paragraph 4

Will be discussed in detail later in presentation.

NDA Regulatory Landscape

Office of New Drugs				
Drug Evaluation I	Drug Evaluation II	Drug Evaluation III	Drug Evaluation IV	Oncology Drug Products
Cardiovascular & Renal	Anesthesia, Analgesia, & Rheumatology	Gastroenterology	Anti-Infective & Ophthalmologic	Drug Oncology
Neurology	Metabolism & Endocrinology	Anti-Viral	Dermatology & Dental	Medical Imaging & Hematology
Psychiatry	Pulmonary & Allergy	Reproductive & Urologic		

ANDA vs. NDA 505(b)(2) Exclusivity

- ANDA
 - 1st to file w/ paragraph IV certification (180 days)
 - Patent protection
- NDA
 - Filing contains required clinical data (3 years)
 - Patent protection

ANDA vs. NDA 505(b)(2) Required Data

- CMC
 - Analytical: same for both
 - Stability:
 - ANDA 3 mo. real-time on 1 batch, accel. 3 mo.
 - NDA 12 mo. real time on 3 batches, accel. 6 mo.
- Safety
 - ANDA not required
 - NDA some usually required

ANDA vs. NDA 505(b)(2) Required Data

- Efficacy
 - ANDA not required
 - NDA usually required
- Patent Certification
 - ANDA required
 - NDA required

ANDA vs. NDA 505(b)(2) Required Data

- Pharmacokinetic

- ANDA

- Single dose fasted BE study (always)
 - Single dose fed BE study (often)

- NDA

- Single dose fasted BA study (always)
 - Single dose food-effect study (almost always)
 - Multiple-dose, SS study (modified release product)

ANDA vs. NDA 505(b)(2) Required Data

- Labeling
 - ANDA
 - Same as RLD
 - Can not list exclusive indications of RLD
 - NDA
 - May be similar to RLD
 - Includes unique data generated for submission
 - Some indications may differ from RLD

ANDA vs. NDA 505(b)(2) Costs

ANDA

\$250,000 - \$500,000 - Normal Healthy – Systemic

\$500,000 - \$1,000,000 - Patients systemic

\$2,000,000 - \$3,000,000 - Patients – Topical

NDA

\$500,000 - \$1,000,000 - BE/ no clinical

\$3,000,000 - 6,000,000 - BE/clinical

ANDA vs. NDA 505(b)(2) Timing

ANDA

- Start of Clinical to Filing – 4+ months
- Filing to Approval – 18+ months

NDA

- Start of Clinical to Filing – 12+ months
- Filing to Approval – 11+ months

ANDA vs NDA 505(b)(2) Marketing Options

- ANDA - Generic Brand
- NDA - Brand Only

NDA 505(b)(2) Examples

- Levothyroxine – DESI to 505(b)(2)

NDA 505(b)(2) Examples

- Canasa – improved release

NDA 505(b)(2) Examples

- Avandamet – new combo

NDA 505(b)(2) Examples

- Clobex – new route of administration

NDA 505(b)(2) Examples

- Myfortic – new form of active ingredient

Questions ?